The research process of novel short peptide-based HIV-1 fusion inhibitors
Acquired immunodeficiency syndrome(AIDS)is a devastating infectious disease caused by the human immunodeficiency virus type 1(HIV-1).T20 is the first approved fusion inhibitor against HIV-1,and plays an important role in AIDS treatment.However,T20 has some problems such as drug resistance,poor metabolic stability in vivo and high cost in clinical use.Therefore,the design of novel peptide fusion inhibitors which can solve the defects of T20 has become a research focus.Short peptides are low-cost to produce and can be modified to improve bioavailability and anti-drug resistance,which is expected to solve the current dilemma of fusion inhibitors.In this paper,the research for short peptide-based fusion inhibitors against HIV-1,such as E-K salt bridge modification,stapled peptide modification,small molecule-peptide conjugation modification,N terminal"M-T hook"of peptide structure optimization and C terminal"IDL tail"of peptide structure optimization were summarized,looking forward to provide valuable reference for the research and development of new anti-HIV-1 drugs.
NETL
NSTL
万方数据
